Tuesday, February 12, 2019

Hormonal Contraceptives Increase the Risk of Suicide and Suicide Attempts

More than 100 million women worldwide use hormonal contraception, and not just to avoid pregnancy. Many have other reasons for using hormonal contraceptives, such as alleviating menstrual pain, heavy bleeding, premenstrual syndrome or acne.

But at what cost?

A 17-year Danish study published in 2017 revealed a startling association between hormonal contraception and the risk of suicide and suicide attempts in women from ages 15 to 33 (Skovlund, 2017). These previously mentally healthy women had no prior history of suicide attempts, psychiatric diagnoses, or antidepressant use.

Yet, there were 6,999 first suicide attempts and 71 suicides among the 475,802 women who were followed in this study for 8.3 years, on average.

And these were just the suicidal behaviors that were known; that is, women who had a recorded diagnosis of suicide attempt or Cause of Death. The real numbers were likely higher.

While the side effects and other risks (such as ischemic stroke) of hormonal contraceptives are well-known, little attention has been paid to this life-threatening potential side effect. And, of course, suicide or attempted suicide is more than just a “side effect.”

Which Hormonal Contraceptives?

If you use hormonal contraceptives, you’re probably wondering: Which hormonal contraceptives are implicated? Here’s the list…

Combined Products

Oral

  • 50 μg Ethinylestradiol (Levonorgestrel);
  • 20-40 μg Ethinylestradiol (Norethisterone, Levonorgestrel, Norgestimate, Desogestrel, Gestodene, Drospirenone, Cyproterone acetate)

Non-oral:

  • Patch (norelgestromin)
  • Vaginal ring (etonogestrel)

Progestin-only products

Oral

  • Progestin-only pills
  • Noresthisterone
  • Desogestrel

Which hormonal contraceptives are the most dangerous? For both suicide and suicide attempts, patch, vaginal ring, and progestin-only products were associated with higher risks than oral combined products. (You can explore the relative risks for specific products below.)

The Hazard Ratio: How High Is the Risk?

Following are some of the most important findings of the 2017 Copenhagen study (Skovlund, 2017):

  • The first couple of months of use are especially dangerous. Compared with never-use, the relative risk of suicide attempt rose twofold one month after initiation of hormonal contraceptive use, peaked after two months of use and remained at least doubled until one year after initiation. After one year of use, the risk decreased, but remained 30% higher (compared to never-users) after more than 7 years of use.
  • Adolescents are at greatest risk. A companion study found that mentally healthy adolescent women using hormonal conception experienced the highest risk of suicide or suicide attempt (Skovlund, 2016). Why? Adolescence, as we all know, is a period characterized by raging hormonal changes, not to mention shifting cultural and social demands — both of which could exacerbate the influence of any additional factor (such as hormonal contraceptives) that might cause mood disturbances. Researchers speculated that another possible factor could be the initiation of a first sexual relationship, which might increase the risk, for some, of a first suicide attempt or suicide.
  • Former hormonal contraceptive use was associated with an increased risk of suicide attempt and suicide. Researchers believed that the decrease in suicide risk after one year of use was likely due to “out-selection” — many women who developed adverse mood reactions while on hormonal contraceptives stopped using them. Sensitivity to mood disturbance (e.g., depression) in these particular women may explain the higher relative risk of suicide attempts and suicide in former users who return to hormonal contraception, rather than the fact that they were former users.

Researchers developed hazard ratios (relative risk) for suicide attempt and suicide for women 15–33 years of age who were hormonal contraception users, as compared with never-users, or those who had never used hormonal contraception.

Here’s how the hazard ratio works…

The never-users hazard ratio = 1.0, for both suicide and suicide attempt. But, as you’ll discover in the following charts, the hazard ratios for hormonal contraception users are all significantly greater than 1.0. (A hazard ratio of 2.0, for example would mean that the hormonal contraceptive user was more than twice as likely as the never-user to attempt suicide.)

General Risk of Suicide Attempt

For all women in the study group, ages 15-33, the overall relative risk among current and recent users was 1.97 for suicide attempt and 3.08 for suicide, compared to never-users.

Former users had a risk of 3.40 for a first suicide attempt and 4.82 for suicide.

Risk of Suicide Attempt By Product
Product Hazard Ratio
Oral
Combined Products
All oral combined 1.91
50 μg Ethinylestradiol
Levonorgestrel 2.78
20-40 μg Ethinylestradiol
Norethisterone 2.03
Levonorgestrel 1.81
Norgestimate 1.92
Desogestrel 1.89
Gestodene 1.88
Drospirenone 2.05
Cyproterone acetate 1.81
Non-Oral
Patch (norelgestromin) 3.28
Vaginal ring (etonogestrel) 2.58
Progestin-only products
Oral
Progestin-only pills 2.29
Noresthisterone 2.77
Desogestrel 2.01
Non-Oral
Implant 4.42
Intrauterine (with levonorgestrel) 2.86
medroxyprogesterone acetate 6.52
Risk of Suicide Attempt By Age Group
Age Group Hazard Ratio
Age 15-19 2.06
Age 20-24 1.61
Age 25-33 1.64

The Depression Factor

Several studies have linked hormonal contraception to depression and adverse mood affects. A separate study by the Copenhagen researchers investigating the association between hormonal contraceptive use and risk of depression (Skovlund et al., 2016) found a 70% higher risk of depression among users of hormonal contraception, compared with never-users. These researchers found that use of hormonal contraception, especially among adolescents, was associated with subsequent use of antidepressants and a first diagnosis of depression.

The irony is that antidepressants, which are often prescribed to prevent suicide, have been linked to impulsive violent and behaviors, including suicide and homicide; in fact, they even carry a black box warning label of suicide risk.

If you’re following the implications here… for these women, the use of contraceptives has now launched a pill chase — they’re now taking a second drug to “fix” the problem that the first drug caused, not to mention that adding an antidepressant further increases the risk of completed suicide, let alone a long list of additional adverse effects. Vicious cycle!

Brain Chemicals and the HPA Axis

The Copenhagen researchers suggest that one explanation for the increased risk in suicidal behaviors is that hormonal contraceptives likely have a direct influence on the neurotransmitters and hypothalamic-pituitary-adrenal (HPA) system involved in stress regulation and the neurobiology of suicidal behaviors (Sokolowski & Wasserman, 2015). The rapid increase in first suicide attempts within a month after initiation of hormonal contraception appears to provide support for this theory.

The HPA axis is a brain-body circuit that plays a critical role in how we respond to stressors; it’s responsible for the neuroendocrine adaptation component of the stress response. It includes three components — the hypothalamus, pituitary gland and adrenal glands — and is regulated by an area of the amygdala, which acts as (the emotion factory — “Alert Central”). The HPA axis is a complex and dynamic intertwining of the central nervous system and endocrine (hormones) system, that when stimulated by stressors, releases “alarm chemicals” such as epinephrine, norepinephrine, cortisol, ACTH (adrenocorticotropic hormone) and CRF (corticotropin-releasing factor).

Hyperactivity of the HPA axis has been associated with major depressive disorder, as well as to suicide attempt in people with depression (Jokinen & Nordstrom, 2009; Li et al., 2013). The Li study found that cortisol levels increased with the increase in severity of depressive symptoms.

But other studies have found that blunted or hypoactive HPA axis activity (such as lower resting cortisol) can also increase the risk for suicide attempt among people with a history of mental health problems (particularly a family history of suicidal behaviors) because it reduces their ability to respond adaptively to ongoing stressors (Melham et al., 2015). And interestingly, those who were taking antidepressants also had lower total output and baseline cortisol levels, which raises the question: Were the antidepressants actually contributing to the increased risk of suicide attempt? A revealing study suggests just that.

The common thread between these HPA axis studies is the parallel fluctuations in cortisol levels and severity of depressive symptoms. So, it’s important to understand that HPA axis dysfunction in depression is a state rather than a trait, which means that it’s always reversible for women who discontinue the use of hormonal contraceptives when they’re dysregulating HPA axis functioning.

So, What should Hormonal Contraceptive Users Do?

It’s important to remember that the 71 suicides and 6,999 first suicide attempts in the Danish study were committed by women who were considered to be mentally healthy before they started using hormonal contraception. Researchers screened for mental health problems, though, in fairness, recognized that some of these women could have had undiagnosed, untreated mental health disorders, or that one may have developed during the 17-year study period.

Still…

Those hazard ratios, which for some hormonal contraceptives, double (or triple or even quadruple) the risk of suicide attempt, demonstrate that women who are using these contraceptives should, at the very least, vigilantly monitor mood, listen to what their bodies are telling them.

Considering the life-threatening severity of this little-recognized potential “side effect” of hormonal contraceptives, you may want to explore other natural alternatives.

The post Hormonal Contraceptives Increase the Risk of Suicide and Suicide Attempts appeared first on Kelly Brogan MD.



from Kelly Brogan MD http://bit.ly/2ByC1Sh

No comments:

Post a Comment